Taken together, dyslipidemia- and inflammation-induced upregulation of IFN-γ receptor, along with elevated IFN-γ in MASLD, likely drive SAMHD1 upregulation in hepatocytes. Here, SAMHD1 is linked to metabolic dysfunction-associated steatotic liver disease.